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Abstract
Background: Reduced libido is widely considered the most prominent symptomatic reflection of low testosterone
(T) levels in men. Testosterone deficiency (TD) afflicts approximately 30% of men aged 40-79 years. This study seeks
to evaluate the effect of a new natural compound “tradamixina “in order to improve male sexual function in
elderly men, particularly libido and possible erectile dysfunction, versus administration of tadalafil 5 mg daily.
Methods: Seventy patients (67.3± 3.7 years) with stable marital relations and affected by reduced libido, with or
without erectile dysfunction were recruited. They were randomly separated in 2 groups A-B of 35. Group A was
administered twice a day a new compound “Tradamixina” (150 mg of Alga Ecklonia Bicyclis, 396 mg of Tribulus
Terrestris and 144 mg of D-Glucosamine and N-Acetyl-D-Glucosamine) for two months, while Group B was
administered tadalafil 5 mg daily, for two months. At visit and after 60 days of treatment patients were evaluated by
means of detailed medical and sexual history, clinical examination, laboratory investigations (Total and Free T),
instrumental examination (NPTR- nocturnal penile tumescence and rigidity test- with Rigiscan). Patients completed a
self-administered IIEF questionnaire (The international index of erectile function) and SQoLM questionnaire (Sexual
quality of life Questionnarie-Male). The results pre and post treatment were compared by Student t test (p<0.005).
Results: After 2 months of treatment in group A serum TT levels (230±18 ng/dl vs 671±14 ng/dl ) and FT levels(56 ±
2.4 pg/ml vs 120 ± 3.9pg/ml) increased, while in group B serum TT levels (245 ± 12 ng/dl vs 247 ± 15 ng/dl ) and FT levels
(53 ± 0.3 pg/ml vs 55 ± 0.5pg/ml) increased not statistically significant. The patient’s numbers with negative NPTR
improved after treatment in group A and B (15 vs 18 and 13 vs 25 respectively). The IIEF total score in group A increased
after treatment with tradamixina (15 ± 1.5 vs 29.77 ± 1.2); the IIEF total score in group B increased slightly (12 ± 1.3 vs
23.40 ± 1.2). The SQoLM total score improved in both groups (A:16 ± 2,3 vs 33 ± 4,1 and B: 16 ± 3,4 vs 31 ± 2,1).
Conclusion: The treatment twice a day with “Tradamixina” for 2 months improved libido in elderly men without
side effects of Tadalafil.
Background
Reduced libido is widely considered the most prominent
symptomatic reflection of low testosterone (T) levels in
men [1,2] . Testosterone deficiency (TD) afflicts approxi-
mately 30% of men aged 40-79 years, with an increase in
prevalence strongly associated with aging and common
medical conditions including obesity, diabetes, and hyper-
tension [3]. Although decreased libido is a concern often
expressed by aging patients [4], it is difficult to measure
comprehensively, being multifactorially determined and
associated with both psychosocial and organic factors [5].
This phenomenon of hypogonadism due to aging has also
been described as testosterone deficiency syndrome, late-
onset hypogonadism, and andropause. Symptoms of this
condition resemble those of ‘normal’ aging and include
changing body composition (osteopenia, increased adipos-
ity, decreased muscle mass), decline in energy and sta-
mina, decreased cognitive function, decreased libido, and
erectile dysfunction [6], systolic hypertension, carotid
artery-wall thickness, increased abdominal visceral-fat
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mass, insulin resistance, reduced HDL concentrations,
postprandial somnolence, impaired quality of life and
depressive mood [7]. Particularly in elderly men, decreased
libido and impotence present a common and important
clinical problem. Sexual dysfunction, encompassing erec-
tile dysfunction, ejaculatory disorders and loss of libido, is
highly prevalent in ageing men and can have substantial
adverse effects on their quality of life [8-11]. Nevertheless
several studies have shown that there is no clear associa-
tion between testosterone levels and erectile function
[9-11]. In fact although androgen replacement has been
shown to enhance sexual function in many elderly men
with low testosterone levels [12,13] it cannot be assumed
that androgen deficiency is responsible for impaired
potency in older men when testosterone levels are in the
normal range. Furthermore, no data is available to judge
the effect of falling testosterone levels as men age when
testosterone concentrations are still within the normal
range [14]. After age 50 the percentage of men who had
experienced their first problems with erection increased
sharply—26% in men age 50 to 59 years and 40% in men
age 60 to 69 years [16-18]. The prevalence of erectile dys-
function increased with increasing age, infact androgens
are essential for the development, growth and maturation
of the erectile tissues. In the animal model testosterone
suppression led to corpora cavernosum atrophy with con-
comitant structural alterations of the dorsal nerve of the
penis, endothelial alterations, reduction of the smooth
muscle component and increase in the deposition of extra-
cellular matrix and cavernosal fibrosis [19,20]. Unlike the
libido, men with a healthy lifestyle and no chronic disease
had the lowest risk for erectile dysfunction; the greatest
difference was seen for men 65 to 79 years of age. The
absolute risk for erectile dysfunction was approximately
10% higher at all ages for men with comorbid conditions
compared with healthy men [21,22]. Testosterone levels in
men begin to decline in the late third or early fourth dec-
ade and diminish at a constant rate thereafter [23]. There
is no universal agreement regarding the exact definition of
hypogonadism. However, it is generally accepted that
hypogonadism refers to the presence of persistently low
circulating testosterone compared with the normal range
derived from healthy young and middle-aged men. This
range is approximately 300-1000 ng/dL or 10.4-34.7 nmol/
L in most assays of serum total testosterone [24], although
wide variation may exist between different commercial
assays [24,25]. In the elderly, the diagnosis of hypogonad-
ism is sometimes problematic because of the difficulty to
know to what extent the previous features are due to
aging, hypogonadism, or both. Longitudinal studies, such
as the Massachusetts Male Aging Study, suggest that total
testosterone decreases at a rate of about 1.6% annually,
with a concomitant 1.3% annual increase in SHBG after
age 40 [23]. The fraction of circulating testosterone that is
bound to SHBG is inactive, so its increase results in even
lower levels of bioavailable testosterone. An estimated 30%
of men aged 70-79 have low serum total testosterone and
approximately 70% have low bioavailable testosterone
levels [27]. The mechanisms causing lower testosterone
levels in healthy elderly men include a decreased respon-
siveness of Leydig cells to luteinizing hormone (LH) and a
blunted compensatory elevation of LH to the lower testos-
terone levels [28]. This study seeks to evaluate the effect of
a new natural compound “tradamixina “ made of Alga
Ecklonia Bicyclis, Tribulus Terrestris and D-Glucosamine
in order to improve male sexual function in elderly men,
particularly libido and possible erectile dysfunction ,versus
the use of tadalafil 5 mg daily. Seven phlorotannins were
isolated and characterized from an edible marine brown
alga Ecklonia Bicyclis, along with three common sterol
derivatives (fucosterol, ergosterol, and cholesterol) accord-
ing to the comprehensive spectral analysis of MS and
NMR data. Compounds 7-phloro eckoland and ,6,6′-bieck-
oll in phlorotannin derivatives were obtained for the first
time with their high respective yields. No bioactive reports
of the compound Fucodiphloroethol G were found to date
[29]. Ecklonia bicyclis has radical scavenger activity 10-100
times more powerful than any other polifenol terrestris
plants, which have only 3-4 fenolic and rings that are com-
monly considered among the most effective antioxidant
molecules. Common polyphenols are soluble in water also
and have a relatively short half-life introduced into the
body. All phlorotannins had antioxidant properties in
vitro, especially, compounds 6,6′-bieckol which showed
the significant activities compared to the other phlorotan-
nins [29]. This capacity is useful like anti-aging and anti-
oxidant, in the aging sexual process. The protodioscin is a
steroidal saponin, which is about 45% of the extract
obtained from aerial parts of Tribulus Terrestris. Thanks
to its particular steroidal structure it has an androgen-
mimetic action, binding and activating the receptor of tes-
tosterone. So this substance is able to increase the endo-
genous production of testosterone, dihydrotestosterone, a
hormone luteinizing hormone (LH), dehydroepiandroster-
one (DHEA) and dehydroepiandrosterone sulfate (DHEA-
S). Because of these effects in experimental animals there
is an increase in spermatogenesis and the frequency of
matches. In the rabbit in particular it has been shown that
the compound stimulates the release of nitric oxide (NO)
by vascular endothelium of the corpora cavernosa thereby
having a pro-erectile effect. The mechanism behind this
effect appears to involve the pathway of steroid hormones.
Although in humans protodioscin is used for the treat-
ment of erectile dysfunction [30,31]. In a placebo-con-
trolled study on a group of young volunteers, were
detected serum levels of testosterone, androstenedione
and luteinizing hormone were detected after administra-
tion of Tribulus terrestris at doses of 10 and 20 mg / kg.
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After 4 weeks of treatment, these values were similar to
those of untreated [33]. Biovis contains polymers of d-glu-
cosamine and n-acetyl-d-glucosamine that act both on
non-adrenergic and non-colinergic system (NANC) and
on endothelial cell system as a strong nitric oxide synthe-
tase (NOS) stimulator [34]. The phosphodiesterase type
5 (PDE5) inhibitor tadalafil can be administered on
demand (5−20 mg) or once daily (2.5-5 mg) to treat erec-
tile dysfunction (ED). Once-daily treatment largely obvi-
ates the need to plan sexual activity within a narrow
therapeutic window after dosing. A number of recent stu-
dies, utilizing the International Index of Erectile Function
−Erectile Function (IIEF-EF) domain [35], as well as the
Sexual Encounter Profile (SEP) questionnaire, as out-
comes, have supported the efficacy of once-daily tadalafil
[36-40].
Methods
A double-blind, randomized design trial was conducted
from January 2012 to May 2012, at our Department of
Urology. Inclusion criteria were: over sixty years of age,
male patients with stable marital relations and affected
by reduced libido (RL), with or without erectile dysfunc-
tion (ED). Exclusion criteria were: diabetes mellitus and
other metabolic disorders (impaired glucose tolerance,
impaired fasting glucose, metabolic syndrome and con-
genital or acquired dyslipidemia), obesity, alcoholism,
smoking, hypertension, cardiovascular disease, Neuro-
genic syndrome (multiple sclerosis, multiple atrophy,
Parkinson’s disease, tumors, stroke, disk disease, spinal
cord disorders, Polyneuropathy, uraemia), Peyronie’s dis-
ease, penile fracture, congenital curvature of penis,
micropenis, hypospadias, epispadias, hyperprolattinemia,
hyper and hypothyroidism, Cushing’s disease, secondary
hypogonadism, or hypogonadotropic hypogonadism,
drug assumption (antihypertensives,, nitrates, antidepres-
sants, antipsychotics, antiandrogens, antihistamines, her-
oin, cocaine and methadone) radiotherapy (pelvis or
retroperitoneum) and lower pelvic surgery (oncological
pelvic surgery, lower urinary and genital tract surgery) and
depression. We enrolled 70 patients, mean age was 67,3±
3,7 years. They were randomly separated in 2 groups A-B
of 35 patients. Group A was administered twice a day a
new compound “Tradamixina” (150 mg of Alga Ecklonia
Bicyclis, 396 mg of Tribulus Terrestris and 144 mg of
D-Glucosamine and N-Acetyl-D-Glucosamine) for two
months, while Group B was administered tadalafil 5 mg
daily, for two months. At visit patients were evaluated by
means of detailed medical and sexual history, clinical
examination, laboratory investigations (Total and Free
Testosterone), and instrumental examination (NPTR- noc-
turnal penile tumescence and rigidity test- with Rigiscan).
Patients completed a self-administered IIEF questionnaire
(The international index of erectile function) and SQoLM
questionnaire (Sexual quality of life Questionnaire-Male).
The therapeutic effects were evaluated by IIEF, SQolM,
Rigiscan and total ad free testosterone levels after 60 days
of treatment. Written informed consent was obtained
from all patients. We asked all patients to complete the
International Index of Erectile Function (IIEF) question-
naire: the IIEF domain was calculated and ED grading was
determined: absent of ED (EF score 26 to 30), mild ED (EF
score 17 to 25), moderate ED (EF score 11 to16) and
severe ED (EF score < 10) [40]. We asked all patients to
complete the Sexual quality of life Questionnarie-Male
(SQoLM) (Pfizer Ltd, Sandwich, UK UK English): this
questionnaire consists of a set of statements, each asking
about thoughts and feelings that the man may have about
his sexual life. The statement may be positive or negative.
They were asked to rate each statement according to how
much they agreed or disagreed. The Sexual Quality of Life
questionnaire Male (SQoL-M) contains 11 items each
with a 6-point Likert-like response scale ranging from
‘completely agree’ to ‘completely disagree’. Items are scored
1-6 (worst to best) and will be scored from Completely
Agree = 1 to Completely Disagree = 6. To allow easy com-
parisons with other measures, raw scores will be trans-
formed onto a standardised scale of 0 to 100 using the
following formula. Scale Score = the sum of the component
items (minus) the lowest possible score* 100/ possible raw
score range. Higher scores imply greater quality of life. For
those questionnaires with missing values, a total score will
be calculated for the individual if at least 50% of the items
have been completed (at least 6 items) using the equation
above. Any questionnaires with >50% missing items will
be removed from the analyses. All patients underwent
nocturnal penile tumescence and rigidity test (NPTR) with
Rigiscan for three consecutive nights. Normal erectile
function was defined with the recording of at least one
erection (70 out of 100% tip rigidity lasting for at least
10 min during either night) [41]: we considered as Nega-
tive Rigiscan (NR) in patients who had an erectile event at
least 70% rigidity recorded on the tip of the penis, which
lasted for 10 minutes or more, and Positive Rigiscan (PR)
in the remaining patients. We practiced this test with the
intent of differentiating organic and psychogenic erectile
dysfunction [42]. Serum testosterone concentrations were
measured using the DPC Coat-A-Count RIA kit, which
has an intra- and interassay coefficient of variation (CV) of
<10% while sex hormone-binding globulin (SHBG) were
measured by ELISA technique (DRG Diagnostics,
Marburg, Germany). We calculated the measurement of
free testosterone from measured total testosterone and
SHBG. These measurements were obtained between 07.00
am and 11.00 am. There is general agreement that total
testosterone levels above 12 nmol/L (346 ng/dL) or free
testosterone levels above 250 pmol/L (72 pg/mL) do not
require testosterone substitution. Similarly, testosterone
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supplementation should be started according to the refer-
ence levels given in the recommendations of the ISA-
ISSAM-EAU [10] when serum total testosterone levels are
below 8 nmol/L (231 ng/dL) or free testosterone levels are
below 180 pmol/L (52 pg/mL) and when serum total tes-
tosterone levels are between 12 and 8 nmol/L or free
testosterone levels are between 250 and 180 pmol/L in
patients with symptoms of testosterone deficiency. So we
considered Normal Testosterone (NT) patients who had
total testosterone levels above 12 nmol/L (346 ng/dL) and
free testosterone levels above 250 pmol/L (72 pg/mL), and
Low Testosterone (LT) patients who had testosterone
levels below 12 nmol/L (346 ng/dL) and free testosterone
levels below 250 pmol/L (72 pg/mL). The study popula-
tion was divided into two groups: patients treated with tra-
damixina and patients treated with tadalafil, and compared
for total score IIEF pre and post treatment , SQolM results
pre and post treatment, mean total and free testosterone
levels pre and post treatment, Rigiscan results pre and
post treatment by Student t test (p<0.005).
Results and discussion
After two months of treatment in group A serum total
testosterone levels (230±18 ng/dl vs 671±14 ng/dl ) and
free testosterone levels(56± 2.4 pg/ml vs 120± 3.9pg/ml)
with(p<0.005) increased, while in group B serum total
testosterone levels (245±12 ng/dl vs 247±15 ng/dl ) and
free testosterone levels(53± 0.3 pg/ml vs 55± 0.5pg/ml)
with(p<0.005) increased but not statistically significant.
In Fig. 1 and 2 we compared the increase of serum total
testosterone levels and free testosterone levels in both
groups. The group treated with tradamixina has increased
total testosterone as well as free testosterone compared to
the group treated with tadalafil. At visit patients were eval-
uated by instrumental examination (NPTR- nocturnal
penile tumescence and rigidity test- with Rigiscan). At
Pre-treatment there were 20 and 22 patients with positive
Rigiscan in group A and group B respectively, while there
were 15 and 13 patients with negative Rigiscan respec-
tively. After the treatment in group A there were 17
patients with positive Rigiscan and 18 patients with nega-
tive Rigiscan, while in group B there were 10 patients with
positive Rigiscan and 25 patients with negative Rigiscan
(Fig 3-4). We asked all patients to complete the Interna-
tional Index of Erectile Function (IIEF) questionnaire.
Fig 5 and 6 show the results of IIEF (singles areas); in
group A and B respectively pre and post treatment. In
group A (Fig 5) the singles areas scores increased after
treatment (area 1 4.70±1.2 vs 8.75±1.6; area 2 2.40±0.8 vs
4.80±1.0; area 3 3.0±0.9 vs 8.50±0.8; area 4 2.50±0.4 vs
3.80±0.9 ; area 5 2.60±0.4 vs 3.90±0.7.) with(p<0.005) , in
group B (Fig 6) also , but with a different trend (area 1
3.50±1.2 vs 10.70±1.5; area 2 2.70±0.7 vs 2.70±0.7; area 3
2.8±0.8 vs 2.80±0.8; area 4 2.70±0.2 vs 3.40 ±0.8 ; area 5
1.30±0.3 vs 3.80±0.60). The IIEF total score in group A
increased after 60 days of treatment with tradamixina
(15±1.5 vs 29.77±1.2); the total score in group B increased
slightly(12±1.3 vs 23.40±1.2) (Fig 7), because in particular
areas the score was not increased, particularly area 1
(group A 4.70±1.2 vs 8.75± 1.6 and group B 3.50±1.2 vs
Fig1 Serum Total Testosterone Level Pre and Post Treatment with
Tadalafil 5mg daily.
Fig.2 Serum Total Testosterone Level Pre and Post Treatment with
Tradamixina.
Fig. 3 Rigiscan Results Pre and Post Treatment with Tradamixina.
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10.70 ± 1.5 ) and area 3 ( group A 3.0±0.9 vs 8.50±0.8 and
group B 2.8±0.8 vs 2.80±0.8).The area 1 is erectile function
while the area 3 the libido (Fig 8). We asked all patients to
complete the Sexual quality of life Questionnarie-Male
(SQoLM). The patients were asked to rate each statement
according to how much they agree or disagree with it
by circling one of the six categories. In group A the total
score improved after treatment (16±2,3 vs 33±4,1
(p<0.005). The total score in group B also improved
(16±3,4 vs 31±2,1). In particular in category 2 “When I
think about my sexual life, I feel Depressed” the improve-
ment in group A was greater than in group B; infact in
group A (2,5±0,3 vs 5,6±0,7(p<0.005)) while in group B
(2,3±0,6 vs 3,6±0,4(p<0.005) ). In category 5 “When I think
about my sexual life, I feel “anxious” the improvement in
group B was greater than in group A, infact in group A
(2,3±0,6 vs 4,7±0,2 (p<0.005)) while in group B (1,5±0,6 vs
5,7±0,3(p<0.005)). In category 6 : “When I think about my
sexual life, I feel like I have lost something” there was an
improvement statistically significant in both groups (group
A 2,7±0,5 vs 5,9±0,1 ; group B 2,4±0,2 vs 5,7±0,3).( Tab.1).
Tradamixina has no side effects, while the most common
side effects with tadalafil were headache (n=5), followed by
nasopharyngitis (n=4), back pain (n=4), dizziness (n=1),
dyspepsia(n=2) (Tab.2). The serum testosterone level
improved in group A because the protodioscin has an
androgen-mimetic action, binding and activating the recep-
tor of testosterone. So this substance is able to increase the
endogenous production of testosterone, dihydrotestoster-
one, a hormone luteinizing hormone (LH), dehydroepian-
drosterone (DHEA) and dehydroepiandrosterone sulfate
(DHEA-S) [30,31].
Hormonal effects of Tribulus Terrestris (TT) were eval-
uated in primates, (rabbit and rat) to identify its usefulness
in the management of erectile dysfunction (ED). TT
extract was administered intravenously, as a bolus dose of
7.5, 15 and 30 mg/kg, in primates for acute study. Rabbits
and normal rats were treated with 2.5, 5 and 10mg/kg of
TT extract orally for 8 weeks, for chronic study. In addi-
tion, castrated rats were treated either with testoster-
one cypionate (10mg/kg, subcutaneously; biweekly for
8 weeks) or TT orally (5mg/kg daily for 8 weeks). Blood
samples were analyzed for testosterone (T), dihydrotestos-
terone (DHT) and dehydroepiandrosterone sulphate
Fig. 4 Rigiscan Results Pre and Post Treatment with Tadalafil 5mg
Daily.
Fig. 5 IIEF Score Pre and Post Treatment with Tradamixina.
Fig. 6 IIEF Score Pre and Post Treatment with Tadalafil 5mg Daily.
Fig. 7 IIEF Total Score Ttradamixina vs Tadalafil mg 5 mg Daily.
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(DHEAS) levels using radioimmunoassay. In primates, the
increases in T (52%), DHT (31%) and DHEAS (29%) at
7.5mg/kg were statistically significant. In rabbits, both T
and DHT were increased compared to control, however,
only the increases in DHT (by 30% and 32% at 5 and
10mg/kg) were statistically significant. In castrated rats,
increases in T levels by 51% and 25% were observed with
T and TT extract respectively that were statistically signifi-
cant. TT increases some of the sex hormones, possibly due
to the presence of protodioscin in the extract. TT may be
useful in mild to moderate cases of ED [32]. Tadalafil
instead of tradamixina doesn’t increased serum testoster-
one levels. In literature there isn’t proof of improvement.
However sustained improvement in sexual function after
12 months of tadalafil administration is associated with
increased T:E ratio mainly related to reduction of E levels.
We hypothesize that androgen-estrogen cross-talk and
possible inhibition of aromatase activity during chronic
exposure to tadalafil might have a role in the regulation of
erectile function [43]. The IIEF total score improved in
group A, because in group B there is a different trend in a
particular area, like area 1 and area 3. In fact in area 1:
erectile function tadalafil shows greater efficacy in men
previously naïve to PDE5−inhibitor therapy. Significantly
higher proportions of subjects receiving once-daily tadala-
fil (vs. placebo) reported improved erections (GAQ1-
Global Assessment Questions and sex lives) (GAQ2- Glo-
bal Assessment Questions). Once-daily tadalafil treatment
also resulted in: 1) significantly higher treatment satisfac-
tion on the EDITS (the Erectile Dysfunction Inventory of
Satisfaction) at endpoint; and 2) significantly improved
psychosocial outcomes, as indicated by increases in the
total score of the SEAR (the Self-Esteem and Relationship
questionnaire) and three of the four SEAR subdomains
compared to placebo. Previous positive findings for
psychosocial outcomes (e.g. sexual self-confidence) and
treatment satisfaction on the EDITS have also been
reported in 20 studies of on-demand tadalafil [44]. Trada-
mixina, however, shows improvement in the same areas
because Biovis contains polymers of d-glucosamine and n-
acetyl-d-glucosamine that act on both the non-adrenergic
and non-colinergic system (NANC) and on the endothelial
cell system as a strong nitric oxide synthetase (NOS) sti-
mulator [32]. Evidence is accumulating that is the CNS,
NO function is essential for erectile responses (Fig. 2). NO
can modulate sexual behavior and penile erection [49] and
may act in several discrete brain regions, eg in the
MPOA63, 64 and the PVN. The area 3 – libido improved
in group A. In fact Tribulus Terrestris is able to increase
the endogenous production of testosterone, dihydrotestos-
terone, a hormone luteinizing hormone (LH), dehydroe-
piandrosterone (DHEA) and dehydroepiandrosterone
sulfate (DHEA-S) [30,31], and so the reduced libido is
widely considered the most prominent symptomatic reflec-
tion of low testosterone (T) levels in men [1,2]. Ecklonia
bicyclis has radical scavenger activity and has antioxidant
properties [30], so it protects the elderly man against aging.
Indeed Tribulus Terrestris, Ecklonia bicyclis and polymers
of d-glucosamine and n-acetyl-d-glucosamine have a
Fig. 8 Area 1 and Area 3 Scores Pre and Post Treatment
Ttradamixina vs Tadalafil 5mg Daily.
Table 1 Sexual Quality of Life Questionnarie-Male Tradamixina vs Tadalafil 5 mg Daily
Area Tradamixina Pre treatment Tradamixina Post treatment Tadalafil 5 mg Pre treatment Tadalafil 5 mg Post treatment
Area 1score 3,3±0,2 5,7±0,4 3,3±1,5 5,3±0,2
Area 2 score 2,5±0,3 5,6±0,7 2,4±0,6 5,6±0,4
Area 3 score 2,2±0,4 5.8±1,2 2,7±0,3 4,3±0,4
Area 4 score 3,0±0,3 5,3±1,5 3,7±0,2 5,2±0,3
Area 5 score 2,3±0,6 4,7±0,2 1,5±0,6 5,7±0,3
Area 6 score 2,7±0,5 5,9±0,1 2,4±0,2 5,7±0,3
Total score area 16±2,3 33±4,1 16±3,4 31±2,1
Table 2 Side Effects of Tradamixina vs Tadalafil 5 mg
Side effects TRADAMIXINA (n=35) TADALAFIL 5mg(n=35)
Headache n=0 n=5
Nasopharyngitis n=0 n=4
Back pain n=0 n=4
dizziness n=0 n=1
dyspepsia n=0 n=2
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synergic anti-aging action [50]. Tadalafil improved the
erectile function but doesn’t improve the libido. The IIEF
total score is higher in group A. The result is guaranteed
by Tribulus Terrestris. In elderly men, decreased libido and
impotence present a common and important clinical pro-
blem, sexual dysfunction (encompassing erectile dysfunc-
tion, ejaculatory disorders and loss of libido) is highly
prevalent in ageing men and can have substantial adverse
effects on their quality of life [51-54]. In fact testosrerone
replacement may have an antidepressant effect in
depressed patients, especially those with hypogonadism
[55]. Tadalafil improved Rigiscan examination and it inhi-
bits PDE-5 at very low concentrations. The efficacy of
PDE-5 inhibitors varies from 40% to 85% depending on the
severity and etiology of ED [56]. As the mechanism of the
PDE-5 inhibitor class requires sufficient NO release
mediated through sexual stimulation, it is not surprising
that there is a “learning” effect in some patients who are
reinitiating sexual activity; although about two thirds of
patients respond within the first two doses, the others only
begin to respond on subsequent dosing reaching a maxi-
mum threshold of response for the study population after
about 6–8 doses [57].
Conclusion
The treatment twice a day with a new compound “Trada-
mixina” (150 mg of Alga Ecklonia Bicyclis, 396 mg of
Tribulus Terrestris and 144 mg of D-Glucosamine and
N-Acetyl-D-Glucosamine) for two months improved
libido in elderly men, with particular symptom of LOH
which can have substantial adverse effects on their quality
of life. This compound is effective in the treatment of
probable mild to moderate erectile dysfunction in LOH
and provides a clear synergistic effect with the administra-
tion of the 3 substances in a single capsule. It can be used
to improve in a natural way the male sexual function due
to its antioxidant, antifibrotic and anti-aging action. Tada-
lafil improves erectile function but not libido, so in LOH it
is not effective for the symptoms. Unlike Tadalafil, Trada-
mixina doesn’t cause side effects and the aim of a valid
treatment for these patients is to “change” the artificial
link “pill-sexuality”- ”pill on demand” reaching the natural
sexual sequence desire-excitation-erection, through a
direct action on the erectile disfunction pathogenesis. So
Tradamixina can be used in LOH for its symptomatic and
preventive action.
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